The Importance of a Clinically-Driven Revenue Cycle
Clinical care claims are the driving force behind any healthcare organization’s revenue cycle....
CID1693
A Phase III Clinical Trial to Evaluate The Safety and Immunogenicity of 23-Valent Pneumococcal Polysaccharide Vaccine
A phase III clinical study was done in a population greater than or equal to 2 years to assess the safety and immunogenicity of a novel 23-valent pneumococcal polysaccharide vaccine (PPV23). Researchers carried out a randomized,...
A Focus on Allergic Asthma, For Allergists eBook
Focus on Allergic Asthma for Allergists.indd
The Role of Mast Cells & Their Progenitors in Allergic Asthma
Evidence suggests that well-known mast cell mediators, such as histamine and bioactive lipids, are responsible for many of the physiological effects observed in the acute phase of allergic reactions. Mast cells located in...
Advances in Asthma & Allergic Disease Genetics
Childhood-onset asthma is associated with the most independent loci compared with other defined groups of asthma and allergic disease cases, according to a review published in The Journal of Allergy and Clinical Immunology....
Biological Therapies for Severe Asthma & Possible Effects on Airway Remodeling
The underlying chronic inflammatory process and airway remodeling (AR) that occur in asthma contribute to the symptomatology of the disease. Today, the most severely ill asthma patients can be treated using a variety of...
Larger Studies In Asthma And Allergic Disease Genetics
Larger studies are needed focusing on genome-wide association studies (GWASs) of asthma and allergic diseases, especially in the patients with childhood-onset asthma and allergic diseases group, and in African American and...
Efficacy And Safety Of Treating Pediatric Patients With Severe Allergic Asthma With Biologicals
This study found there was high certainty for patients with asthma between 6-12 years old that used omalizumab to experience decreased annual exacerbation rate, improved quality of life (QoL), and reduced ICS and rescue...
Omalizumab Efficacy Trial Data Confirmed With Real-World Evidence
“Consistent improvements in Global evaluation of treatment effectiveness (GETE), lung function, and patient-reported outcomes (PROs), and reductions in asthma exacerbations, oral corticosteroid (OCS) use, and healthcare resource...
Omalizumab Efficacy in Allergic Asthma Unaffected by Comorbidity Burden
Previous studies indicate that patients with asthma commonly have comorbidities, which may complicate their response to treatment. To examine the response omalizumab in patients with moderate-to-severe allergic asthma by both...
Omalizumab Especially Beneficial for SAA With Multiple Allergic Comorbidities
Prior research indicates that IgE-mediated phatophysiological mechanisms often occur in allergic diseases, including severe allergic asthma (SAA). With the hypothesis that the anti-IgE monoclonal antibody omalizumab might...
